Abbott Laboratories (BIT:1ABT)
Italy · Delayed Price · Currency is EUR | Market Cap | 141.20B -33.7% |
| Revenue (ttm) | 39.14B +6.6% |
| Net Income | 5.42B -53.5% |
| EPS | 3.10 -53.6% |
| Shares Out | n/a |
| PE Ratio | 26.04 |
| Forward PE | 16.87 |
| Dividend | 2.15 (2.50%) |
| Ex-Dividend Date | Jan 14, 2026 |
| Volume | 314 |
| Average Volume | 267 |
| Open | 86.58 |
| Previous Close | 85.84 |
| Day's Range | 82.00 - 86.58 |
| 52-Week Range | 81.18 - 120.94 |
| Beta | n/a |
| RSI | 24.86 |
| Earnings Date | Apr 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings
Abbott Laboratories (NYSE: ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations.
Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks
The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion.
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.
Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Abbott first-quarter results beat on cancer diagnostics, medical device strength
Abbott marginally beat Wall Street estimates for quarterly profit and revenue on Thursday, partially helped by its newly acquired cancer diagnostics business.
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncolog...
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings
Abbott Laboratories (NYSE: ABT) will release earnings for its first quarter before the opening bell on Thursday, April 16.
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for prematur...
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9...
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment...
Abbott hosts conference call for first-quarter earnings
ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ Learn more at Cologuard.com/TheTalk ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (N...
Abbott completes acquisition of Exact Sciences
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABB...
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions...
Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit
MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio, one of the world's leading innovative agtech companies, will be taking the stage at the World Agri-Tech Innovation Summit taking place March 16–18, 2026. Chris...
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 Improve...
Exact Sciences Stockholders Approve Acquisition by Abbott
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted t...
Abbott declares 409th consecutive quarterly dividend
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/23...
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) Sys...
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Abbott faces India scrutiny in cough syrup abuse investigation, documents show
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
Abbott Laboratories Raised Prices, Prompting Sales Slump
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.